| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
|
Zimling, Zarah Glad
|
|
2012
|
70 |
5 |
p. 743-754
|
article
|
| 2 |
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
|
Salazar, R.
|
|
2012
|
70 |
5 |
p. 673-681
|
article
|
| 3 |
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer
|
Shim, Hyun-Jeong
|
|
2012
|
70 |
5 |
p. 683-690
|
article
|
| 4 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02
|
Choi, Yoon Hee
|
|
2012
|
70 |
5 |
p. 665-672
|
article
|
| 5 |
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?
|
Wardill, Hannah R.
|
|
2012
|
70 |
5 |
p. 627-635
|
article
|
| 6 |
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors
|
Dubbelman, Anne-Charlotte
|
|
2012
|
70 |
5 |
p. 653-663
|
article
|
| 7 |
Erratum to: The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
|
Glaros, Trevor G.
|
|
2012
|
70 |
5 |
p. 763-764
|
article
|
| 8 |
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
|
Dong, Song
|
|
2012
|
70 |
5 |
p. 707-716
|
article
|
| 9 |
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
|
Infante, Jeffrey R.
|
|
2012
|
70 |
5 |
p. 699-705
|
article
|
| 10 |
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer
|
Goya, Hiroki
|
|
2012
|
70 |
5 |
p. 691-697
|
article
|
| 11 |
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer
|
Fukuda, Minoru
|
|
2012
|
70 |
5 |
p. 645-651
|
article
|
| 12 |
Phase I trial of pomalidomide given for patients with advanced solid tumors
|
Cooney, Matthew M.
|
|
2012
|
70 |
5 |
p. 755-761
|
article
|
| 13 |
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy
|
Kang, Byung Woog
|
|
2012
|
70 |
5 |
p. 735-741
|
article
|
| 14 |
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
|
Farrell, Colm
|
|
2012
|
70 |
5 |
p. 727-734
|
article
|
| 15 |
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy
|
Chen, Y. Z.
|
|
2012
|
70 |
5 |
p. 637-644
|
article
|
| 16 |
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
|
Chen, N.
|
|
2012
|
70 |
5 |
p. 717-725
|
article
|
Journal description